Elevated high mobility group A2 expression in liver cancer predicts poor patient survival

• Yue-Chen Zhao ^[3] ; Yan Jiao ^[1] ; Yan-Qing Li ^[1] ; Zhuo Fu ^[2] ; Zhao-Ying Yang ^[4] ; Miao He ^[3]
  1. [1] Jilin University

     Jilin University

     China

     
  2. [2] First Hospital of Jilin University

     First Hospital of Jilin University

     China

     
  3. [3] The Second Hospital of Jilin University. Changchun, Jilin. China
  4. [4] China-Japan Union Hospital of Jilin University. Changchun, Jilin. China

  Mostrar afiliaciones +
• Localización: Revista Española de Enfermedades Digestivas, ISSN-e 2340-4167, ISSN 1130-0108, Vol. 112, Nº. 1, 2020, págs. 27-33
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Background: liver cancer is a malignant tumor with a high morbidity and mortality that endangers human health. High mobility group A2 (HMGA2) is a chromosome associated protein that participates in embryogenesis, tissue development, tumorigenesis and development. Objective: to explore the relationship between HMGA2 expression and the clinicopathological parameters and survival of liver cancer patients using The Cancer Genome Atlas Liver Hepatocellular Carcinoma (HCC) data. Methods: RNA-sequencing data and the corresponding clinical characteristics of the patients were downloaded from the Atlas database. The Chi-squared test was used to assess the relationship between HMGA2 expression and clinical variables. Cox regression analysis was used to compare survival rates between the high- and low-expressing groups; the p-values and Kaplan-Meier survival curves were compared using the log-rank test. Results: RNA-seq data from 373 cases of liver cancer cases were analyzed. HMGA2 was overexpressed in liver cancer and significantly associated with gender (p = 0.0357), T classification (p = 0.0063), clinical classification (p = 0.0026) and overall survival (p = 0.0386). According to the multivariate analysis, HMGA2 could independently predict overall survival in liver cancer. Conclusions: HMGA2 independently predicts poor prognosis in liver cancer and serves as a molecular marker to determine disease prognosis.